ARA290/Poziotinib is an EPO derivative and a specific erythropoietin/CD131 heteroreceptor agonist, commonly used in the treatment of neurological diseases. ARA290 enhances the proliferation, migration and resistance to H2O2-induced apoptosis of endothelial colony-forming cells (ECFCs). ARA290 is an EPO analog peptide that has no hematopoietic side effects but may have neurotrophic and antidepressant effects.

Purity: >98% (or refer to the Certificate of Analysis)

Semaglutide is a new generation GLP-1 (glucagon-like peptide-1) analogues. Semaglutide is a long-acting dosage form based on the basic structure of liraglutide, which is more effective in the treatment of type 2 diabetes mellitus. Compared with lilarlutide, somalutide has a longer aliphobic chain and an increased hydrophobicity, but somalutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced.PEG modification can not only tightly bind to albumin, cover up the DPP-4 enzymatic hydrolysis site, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation.

Molecular Weight: 4813.45

Appearance: White Powder

Purity (HPLC): ≥99.0%

Single Impurity (HPLC): ≤1.0%

Moisture Content (Karl Fischer): ≤10.0%

Peptide Content: ≥80.0%

Storage: Store at -20℃ degrees Celsius in a dry and cool place.